<div id="readability-page-1"><div>                     <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/prokidney-corp-logo-1200x675.png/query-dj0yMDI0MDUyMDE1MjM1NA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/prokidney-corp-logo-1200x675.png/query-dj0yMDI0MDUyMDE1MjM1NA"/>ProKidney Corp. (NASDAQ:PROK - Get Free Report) Director Brian Jg Pereira sold 502,136 shares of ProKidney stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $2.37, for a total value of $1,190,062.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.</p><p>Brian Jg Pereira also recently made the following trade(s): </p><ul><li>On Wednesday, November 12th, Brian Jg Pereira sold 255,026 shares of ProKidney stock. The stock was sold at an average price of $2.72, for a total transaction of $693,670.72. </li></ul><h2>ProKidney Trading Up 5.7%</h2><p>Shares of PROK traded up $0.13 during trading hours on Friday, reaching $2.41. 1,336,204 shares of the stock traded hands, compared to its average volume of 1,643,471. ProKidney Corp. has a 52 week low of $0.46 and a 52 week high of $7.13. The company has a market cap of $709.21 million, a price-to-earnings ratio of -4.38 and a beta of 1.75. The stock has a fifty day simple moving average of $2.81 and a 200 day simple moving average of $2.13. </p><p>ProKidney (NASDAQ:PROK - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.12). The business had revenue of $0.22 million during the quarter, compared to analysts' expectations of $0.04 million.  Analysts predict that  ProKidney Corp. will post -0.57 earnings per share for the current fiscal year. </p><h2>Hedge Funds Weigh In On ProKidney</h2><hr/><hr/><p>Several hedge funds have recently made changes to their positions in PROK. Zullo Investment Group Inc. purchased a new stake in  ProKidney during the 3rd quarter worth about $28,000.  Catalyst Funds Management Pty Ltd purchased a new stake in shares of  ProKidney in the second quarter worth about $36,000.  AQR Capital Management LLC boosted its position in shares of  ProKidney by 106.4% in the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company's stock valued at $46,000 after acquiring an additional 27,098 shares during the period.  Deutsche Bank AG grew its stake in  ProKidney by 49.4% during the first quarter. Deutsche Bank AG now owns 86,337 shares of the company's stock valued at $76,000 after acquiring an additional 28,546 shares in the last quarter.  Finally, Jefferies Financial Group Inc. bought a new stake in  ProKidney during the 3rd quarter worth approximately $158,000. 51.59% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of analysts recently issued reports on the stock. Zacks Research downgraded shares of ProKidney from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, August 18th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of ProKidney in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock  has an average rating of &#34;Hold&#34; and a consensus target price of $6.25.</p><p><b>Check Out Our Latest Analysis on PROK</b></p><h2>ProKidney Company Profile</h2><p> (Get Free Report)</p><p>ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than ProKidney</li><li>What Are Growth Stocks and Investing in Them </li><li>Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever</li><li>What is a Low P/E Ratio and What Does it Tell Investors?</li><li>MarketBeat Week in Review – 11/10 - 11/14</li><li>What is a Dividend Harvesting Strategy and How Can Investors Profit from it?</li><li>Are These 3 Oversold Tech Giants Ready to Rebound?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at ProKidney?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for ProKidney and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251013195604_pushtrumpnew-3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251013195604_pushtrumpnew-3.jpg"/></p><div><p>NEW LAW: Congress Approves Setup For Digital Dollar?</p><p>Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0  But according to Rep. Marjorie Taylor ...</p><p><span>Goldco Precious Metals</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTg0Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTg0Mw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251031131011_pushai-1.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251031131011_pushai-1.jpg"/></p><div><p>Nvidia Chief: Billions Could Flow Here Next…</p><p>This Feels Like Collecting ‘Toll Money’ From AI…   Every time AI ‘thinks,’ data has to move, and that moveme...</p><p><span>Stocks To Trade</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTgzNA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTgzNA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/Screenshot%202025-07-30%20at%201.42.22%E2%80%AFPM.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="797" height="420" original-src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/Screenshot%202025-07-30%20at%201.42.22%E2%80%AFPM.png"/></p><div><p>Capital Gains Tax Strategies for Seniors</p><p>Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...</p><p><span>SmartAsset</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTg3Nw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTg3Nw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2067push_AI-9.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2067push_AI-9.jpg"/></p><div><p>Everyone’s watching Nvidia right now. Here’s why I’m excited.</p><p>So, unless you’ve been living under a rock, you probably saw the news…  Nvidia just signed a $7 BILLION deal...</p><p><span>Timothy Sykes</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTc3OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTc3OA"/></p></div></div><div><p></p><div><p>Gold’s rally is big — but what comes next could be bigge</p><p>Gold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...</p><p><span>Weiss Ratings</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjAxOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjAxOQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251105140427_pushradintel3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251105140427_pushradintel3.jpg"/></p><div><p>$0.81/Share. 10,000+ Investors. Window Closing Fast.</p><p>This is your final shot before the next potential surge. RAD Intel has already raised over $50 million from mo...</p><p><span>RAD Intel</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTk3Mw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTk3Mw"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2049push_book-stack.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="213" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_2049push_book-stack.png"/></p><div><p>Jerome Powell just made me a fortune (and my enemies)</p><p>The Fed rate cut truth they don't want you to know  The Fed's 25 basis point cut isn't just monetary policy…...</p><p><span>Crypto 101 Media</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTQzOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTQzOA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250609131037_pushelonnew-6.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250609131037_pushelonnew-6.jpg"/></p><div><p>Nvidia CEO Issues Bold Tesla Call</p><p>While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTc5Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNTc5Mg"/></p></div></div></div>                     </div>                 </div></div>

PROK

<p>ProKidney Corp. Director Brian Jg Pereira sold 502,136 shares of the company's stock for $1,190,062.32 on November 13th. The transaction was disclosed in an SEC filing. Pereira also sold 255,026 shares on November 12th for $693,670.72. ProKidney's stock rose 5.7% to $2.41, with a market cap of $709.21 million. Analysts have mixed ratings on the stock, with a consensus target price of $6.25. The company is a clinical-stage biotech firm focused on kidney disease therapies.</p>

ProKidney (NASDAQ:PROK) Director Sells $1,190,062.32 in Stock